Literature DB >> 10816656

Molecular basis of the alpha-MSH/IL-1 antagonism.

T Brzoska1, D H Kalden, T Scholzen, T A Luger.   

Abstract

The neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) is recognized as a potent mediator of immune and inflammatory reactions. Accordingly, alpha-MSH in vitro, as well as in vivo, antagonizes the proinflammatory activities of cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor alpha (TNF alpha). Since the molecular basis of these antiinflammatory effects is not well known, the influence of alpha-MSH on IL-1 beta-induced chemokine production and transcription factor activation was investigated in human keratinocytes. alpha-MSH, in a dose-dependent manner, after 48 h, significantly reduced the IL-1 beta mediated secretion of the C-X-C chemokines IL-8 and Gro alpha. This was confirmed by semiquantitative RT-PCR, which revealed a marked down-regulation in IL-8 and Gro alpha mRNA expression. Furthermore, we determined the effect of alpha-MSH on the IL-1 beta-induced activation of the nuclear factor kappa B (NF kappa B)--a major transcription factor for chemokine genes. Electrophoretic mobility-shift-assays showed that alpha-MSH, in a dose range from 10(-6) to 10(-12) M, significantly downregulated the IL-1 beta-induced activation of NF kappa B 10 minutes after stimulation. Therefore, NF kappa B inactivation by alpha-MSH appears to be a crucial event, one that is responsible for the downregulation of cytokine gene transcription.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10816656     DOI: 10.1111/j.1749-6632.1999.tb08680.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  16 in total

Review 1.  MC1R, eumelanin and pheomelanin: their role in determining the susceptibility to skin cancer.

Authors:  Tahseen H Nasti; Laura Timares
Journal:  Photochem Photobiol       Date:  2014-11-07       Impact factor: 3.421

2.  Interleukin-1β (187-207)-induced hyperthermia is inhibited by interleukin-1β (193-195) in rats.

Authors:  Miklós Palotai; Edina Kiss; Zsolt Bagosi; Miklós Jászberényi; Gábor Tóth; Györgyi Váradi; Gyula Telegdy
Journal:  Neurochem Res       Date:  2013-12-13       Impact factor: 3.996

Review 3.  Negative regulators that mediate ocular immune privilege.

Authors:  Andrew W Taylor; Tat Fong Ng
Journal:  J Leukoc Biol       Date:  2018-02-12       Impact factor: 4.962

4.  Alpha-melanocyte stimulating hormone inhibits monocytes adhesion to vascular endothelium.

Authors:  Yang Yang; Weihua Zhang; Lin Meng; Haitao Yu; Na Lu; Gang Fu; Yang Zheng
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-20

Review 5.  Applications of the role of α-MSH in ocular immune privilege.

Authors:  Andrew W Taylor; Darren Lee
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 6.  [Alpha-melanocyte-stimulating hormone. Its current significance for dermatology].

Authors:  M Böhm; T A Luger
Journal:  Hautarzt       Date:  2004-05       Impact factor: 0.751

7.  The neuropeptides α-MSH and NPY modulate phagocytosis and phagolysosome activation in RAW 264.7 cells.

Authors:  Toan A Phan; Andrew W Taylor
Journal:  J Neuroimmunol       Date:  2013-05-17       Impact factor: 3.478

8.  Crucial role of the melanocortin receptor MC1R in experimental colitis.

Authors:  C Maaser; K Kannengiesser; C Specht; A Lügering; T Brzoska; T A Luger; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

9.  The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) therapy.

Authors:  Andrew W Taylor; Nobuyoshi Kitaichi
Journal:  Brain Behav Immun       Date:  2008-01-02       Impact factor: 7.217

10.  Neuroprotective effects of melanocortins in experimental spinal cord injury. An experimental study in the rat using topical application of compounds with varying affinity to melanocortin receptors.

Authors:  H S Sharma; A Skottner; T Lundstedt; M Flärdh; L Wiklund
Journal:  J Neural Transm (Vienna)       Date:  2006-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.